Journal of Mind and Medical Sciences

https://scholar.valpo.edu/jmms/
https://proscholar.org/jmms/

ISSN: 2392-7674

Management of systemic lupus erythematosus in pregnancy

Oana Denisa Bălălău[1,2*], Mihai George Loghin[1,2], Delia Maria Bogheanu[2], Nicolae Bacalbasa[1], Anca Daniela Stănescu[1,2], Daniela Gabriela Bălan[3], Ioana Păunică[1], Octavian Gabriel Olaru[1,2]

[1]*Carol Davila University of Medicine and Pharmacy, Bucharest, Romania*
[2]*Bucur Maternity, St. John Emergency Clinical Hospital, Bucharest, Romania*
[3]*Carol Davila University of Medicine and Pharmacy, Department of Physiology, Bucharest, Romania*

ABSTRACT

Systemic lupus erythematosus is one of the most common autoimmune disorders affecting young women. Pregnant women with lupus are generally at higher risk for certain pregnancy complications than women without comorbidities. Even so, a pregnancy with lupus can be carried to term in optimal conditions if it is properly managed by a doctor. Monitoring is generally recommended six months after the onset of lupus symptoms, and ideally there should be no active lupus symptoms prior to conception. General screening tests should include the anti-phospholipid, anti-Ro and anti-La antibodies. Women who are positive for these antibodies have an increased risk of congenital heart block in the fetus. In addition, pregnant women with lupus have an increased risk of spontaneous abortion, intrauterine fetal growth restriction, pre-term birth, while neonatal lupus syndrome is a major fetal condition. The maternal risks are faced with disease flares, pre-eclampsia and other complications. Treatment options during pregnancy are limited to a few safe medications. For example, prednisone is unlikely to cause fetal malformations, but it increases the risk of diabetes and high blood pressure in the mother. Consequently, a careful multidisciplinary monitoring is essential for optimal results in pregnancy with lupus.

Category: Review

Received: March 11, 2022
Accepted: June 02, 2022
Published: October 15, 2022

Keywords:

pregnancy, systemic lupus erythematosus, antiphospholipid antibodies, autoimmune disease

* **Corresponding author:**

Oana Denisa Bălălău,

Carol Davila University of Medicine and Pharmacy, Bucur Maternity, St. John Emergency Hospital, Bucharest, Romania

E-mail: doctor.balalau@gmail.com

Introduction

Systemic lupus erythematosus is a chronic autoimmune disease of unknown cause that can affect all organs. It is characterized by a vast heterogeneity of clinical manifestations and immunological abnormalities that it presents. Most frequently, patients with systemic lupus erythematosus have increased levels of antinuclear antibodies (ANA), anti-double-stranded DNA antibodies (anti-dsDNA) and anti-Smith antibodies (anti-Sm) [1].

Due to the heterogeneity of clinical manifestations the diagnosis of systemic lupus erythematosus (SLE) is difficult, often being one of exclusion. For this reason, classification criteria were developed and they guide the physician towards the diagnosis of systemic lupus erythematosus [2].

In 2012, the SLICC classification criteria were developed. In order to formulate the diagnosis, we must have at least four criteria; mandatory a clinical criterion and an immunological criterion or a histopathological examination with a diagnosis of lupus nephritis [3,4].

The clinical criteria include acute skin manifestation (except the discoid lesions), chronic skin lesions, which can be associated with other autoimmune diseases, the most common being an overlap syndrome with lichen planus [3-5]. Alopecia is another criterion included. It is characterized by fragility of the hair, breaking easily not far from the emergence point; it is important to exclude alopecia areata (this is frequently associated with celiac disease) or iron depletion. Nasal or oral lesions with the appearance of ulcers constitute another criterion. Joint damage which is frequently the first sign of the disease, represent other clinical diagnostic criteria. Patients can have central or peripheral neurological symptoms, the clinical manifestations including: cranial neuropathy, myelitis, psychosis, depression, seizures, encephalitis. In the absence of uremia, serositis represents classification criteria - pleurisy or pericarditis that last for at least 24

To cite this article: Bălălău OD, Loghin MG, Bogheanu DM, Bacalbasa N, Stănescu AD, Balan DG, Păunică I, Olaru OG. Management of systemic lupus erythematosus in pregnancy. *J Mind Med Sci*. 2022;9(2):236-241. doi: 10.22543/2392-7674.1358

hours. Hemolytic anemia, leukopenia (less than 4000/mm^3 or lymphocytes less than 1000/mm^3), as well as platelets less than 100,000/mm^3 that is another criterion for the severity of the disease [3,4].

The immunological criteria are: increase above the laboratory reference value of anti-nuclear antibodies (ANA), more than two-times increase in anti-double-stranded DNA antibodies level, presence of anti-Smith antibodies, positive Coombs test, in the absence of hemolytic anemia, decrease of complement components: C3, C4, CH50 or the presence of antiphospholipid syndrome components [3,6].

Discussion

The literature search was conducted in several international databases (PubMed, Scopus, Clarivate, etc.) using the following terms: systemic lupus erythematosus, preeclampsia in lupus, lupus nephritis and immunological outcome. No date restriction was applied. Language was restricted to English, French and Spanish. Additional studies from the reference list of the articles were searched.

Generally, the fertility is not affected by systemic lupus erythematosus, but the specific treatment of the disease affects it, especially the treatment with Cyclophosphamide. Patients with systemic lupus erythematosus have a high maternal risk, the best prognosis for pregnancy is after the patient achieves remission and maintains it for six months. Active disease is a bad prognostic factor for both the mother and the fetus [6-8].

An observational study led by Buyon that included 385 patients with systemic lupus erythematosus with disease in remission or mild-moderate forms of active disease discovered 81 pregnant women (21.04%) without obstetric risk. After controlling the risk factors (for example hypertension, thrombocytopenia, flares or moderately active disease), the risk of developing obstetric complications among the Caucasian population decreased from 79% to 8%. This study did not include patients with severe systemic lupus erythematosus, active lupus nephritis, uncontrolled hypertension or diabetes [9].

A study by Clowse et al. that included 267 patients with systemic lupus erythematosus found that patients with active disease have a higher risk of abortion, compared to patients with the mild form. However, there were no statistically significant differences regarding the number of live births between the two forms (77% versus 88%) [6].

Before conception, it is important for the rheumatologist to assess the remission status of the disease, target organ damage, and hypercoagulability status. The obstetrician must discover the events that may indicate a high-risk pregnancy, for example the antecedents of small for gestational age, preeclampsia, stillbirth, abortion and prematurity. For patients with lupus nephritis, the active form, it is recommended to be in remission for at least six months before conception. Other risk factors that must be evaluated are episodes of recent transient ischemic vascular accidents, cardiac syndromes, pulmonary hypertension, diffuse interstitial pneumopathy - either due to the disease, or due to fibrosis caused by methotrexate treatment, renal failure, etc. [10,11]. Antibodies against Ro/SSA and antibodies against La/SSB must be evaluated, because they cause neonatal lupus [10].

In addition to the tests recommended for all patients who want to get pregnant, in patients with systemic lupus erythematosus it is necessary to evaluate their liver and kidney functions (transaminases, bilirubin, urea, serum creatinine, albumin/creatinine ratio, urine summary and urinary sediment). Disease-specific investigations are also mandatory: anti-Ro antibodies, anti-La antibodies, anti-double-stranded DNA antibodies, lupus anticoagulant, anti-beta2-glycoprotein I antibodies (both IgG and IgM), anticardiolipin antibodies (IgG and IgM) and complement (CH50 fractions, C3, C4) (Figure 1) [11].



Figure 1. Evaluation protocol of pregnant women with systemic lupus erythematosus

During the pregnancy, the exacerbation of lupus is frequent with the appearance of flares. The frequency is 25-60%, depending on the geographical area and the race [8,11-13]. Risk factors for flares are represented by active disease less than six months [6], history of lupus nephritis [12-14], lack of treatment with hydroxychloroquine, primiparity [15-17], the presence of antiphospholipid antibodies and thrombocytopenia [9,18].

Another study led by Clowse et al. that included 13,555 patients with systemic lupus erythematosus concluded that they have a two to four times greater risk of developing preeclampsia, eclampsia, premature birth, intrauterine growth restriction, thrombosis, thrombocytopenia and infection [19]. Mortality is twenty times higher compared to the mortality of patients without lupus, but if the compared groups are pregnant and non-pregnant patients with systemic lupus erythematosus, the mortality in the first group was lower than in the second group [19].

A study by Yasmeen et al. analyzed the risk of hypertension associated with pregnancy, postpartum

hemorrhage, deep vein thrombosis and prematurity. The patients included in this study had a higher risk, compared to the general population of developing such complications [20].

Preeclampsia is one of the most common maternal complications that can occur. Its frequency is 16-30%, compared to 4.6% among the population without lupus [8, 21-23]. This most frequently occurs in patients with a history of lupus nephritis, the decrease in complement values as a result of its consumption and thrombocytopenia [21,24].

Prematurity is a very frequent neonatal complication, occurring between 15-50% of pregnancies, compared to 12% among the general population [16]. It is most frequently associated with lupus nephritis.

Patients with active lupus nephritis have an increased risk of abortion, especially if they also have antiphospholipid syndrome. The risk of intrauterine growth restriction is 10-30%, with higher values in patients with arterial hypertension, active systemic lupus erythematosus, lupus nephritis [20].

Neonatal lupus is more common in children from mothers with anti-Ro or anti-La antibodies. The most frequent manifestations among newborns are lupus skin eruptions and atrioventricular conduction disorders (atrioventricular blocks or bundle branch blocks). In addition to SLE, patients with Sjögren's syndrome have anti-Ro antibodies and anti-La antibodies in their serum, so newborns can show clinical manifestations of lupus [25].

During pregnancy, patients with lupus nephritis must be carefully evaluated. An observational study led by Gladman that included 104 patients with systemic lupus erythematosus, of which 81 had kidney disease, concluded that the frequency of small for age is very high [15]. A retrospective study by Saavedra et al. included 95 pregnancies with history of lupus nephritis, concluded that the risk of complications is 88%, versus 43% among patients without kidney disease. Also, the risk of flares was 54% versus 25%. Episodes of nephritis reactivation responded well to high-dose glucocorticoid therapy [16]. Patients with antiphospholipid syndrome must receive a personalized evaluation (see Table 1) [26].

The first visit to the specialist must include a general clinical exam, including blood pressure measurement, evaluation of renal and hepatic function, immunological evaluation: anti-Ro antibodies, anti-La antibodies, lupus anticoagulant, anticardiolipin antibodies, anti-double-stranded DNA antibodies, CH50, C3, C4 [27].

Maternal-fetal monitoring includes, in addition to routine monitoring, first-trimester ultrasound to accurately determine gestational age and probable date of birth. At 18 weeks, it is mandatory to evaluate the fetal anatomy, including cardiac evaluation to determine if there is a heart conduction disorder. In the third trimester, patients must undergo an ultrasound evaluation to determine if there is small for gestational age, intrauterine growth restriction or placental failure. The evaluation is performed at every four weeks if the pregnant woman does not have any of the listed complications. Evaluation by nonstress test or biophysical profile is mandatory in the last four to six weeks of pregnancy [27].

Table 1. Associated risks on patients with active disease

	Gladman	Webster	Saavedra
Study type	observational	retrospective	retrospective
No. patients	193	90	95
Renal active disease	81	47	35
Risk of premature birth	p>0.05	P=0.002	-
Maternal complications	High risk	P<=0.001	P=0.00001
Relapse	High risk	P=0.004	-
Fetal outcome	P>0.05	p>0.05	P=0.031 calculated risk for stillbirth

Preeclampsia is a frequent pathology associated with pregnancy, especially among patients with systemic lupus erythematosus. After twenty weeks of amenorrhea, all patients must have their blood pressure evaluated, proteinuria determined for twenty-four hours, and target organ dysfunction evaluated. From the gestational age of 12 weeks, low-dose aspirin should be introduced to reduce the risk of preeclampsia by 2-5%. It is very important to make the differential diagnosis with lupus nephritis. In case of kidney disease, proteinuria occurs, the urinary sediment is loaded, it shows leukocytes, red blood cells and cells arranged in clusters, the complement is low, and the antibodies against double-stranded DNA are increased. The criteria favoring preeclampsia are: thrombocytopenia, increased liver enzymes and uric acid [28-30].

On the course of pregnancy, patients can receive treatment with hydroxychloroquine which reduces the risk of flares [31-33]. A study led by Levy that included 20 pregnant women observed that there were no differences regarding the frequency of flares, but observed that patients treated with hydroxychloroquine required lower doses of glucocorticoid and had lower activity scores [34]. In addition to these benefits, hydroxychloroquine decreases the risk of neonatal heart abnormalities [35-38].

Aspirin is indicated from twelve weeks of pregnancy to all pregnant women with lupus. It appears to reduce the risk of preeclampsia [39-41].

In addition to these two, we can also administer non-steroidal anti-inflammatory, in order to keep SLE under control, but with caution after 20 weeks of amenorrhea. Keep in mind that after 30 weeks of amenorrhea they are contraindicated. There is a low risk of developing

oligohydramnios. Glucocorticoids are administered in the lowest effective dose, preferably less than 10 mg/day [42-44].

Administration in the first trimester of pregnancy can be associated with cheiloschisis (cleft lip) or cheilopalatoschisis (cleft palate) [11]. Azathioprine can be administered in a maximum dose of 2 mg/kg/day. Cyclosporine is allowed in pregnancy, tacrolimus is useful in lupus nephritis [45,46]. Immunomodulatory therapy with anti-CD20 antibodies: Rituximab or with BAFF inhibitors: Belimumab is allowed in pregnancy, because these are IgG that do not cross the fetal placental barrier [11,47-49].

During pregnancy, it is contraindicated to administer cyclophosphamide. as it can cause fetal malformations. However, in severe cases, Mycophenolate mofetil, Methotrexate and Lefunomide can be administered in the third trimester. If the patient has been administered Lefunomide, treatment must be stopped and Cholestriamine must be administered [11,47-49].

Breastfeeding is encouraged after birth. Patients following therapy with hydroxychloroquine, glucocorticoid, cyclosporine, azathioprine, tacrolimus or biological therapy can breastfeed. Breastfeeding is contraindicated if the patient is undergoing treatment with methotrexate, mycophenolate mofetil, cyclophosphamide, lefunomide [50-52].

Conclusions

Patients with systemic lupus erythematosus present an increased obstetric risk; the presence of lupus nephritis represents an important risk factor for the occurrence of preeclampsia, intrauterine growth restriction.

It is important to make a differential diagnosis after 20 weeks of amenorrhea between preeclampsia and lupus nephritis. The risks of thromboembolic disease, post-partum hemorrhage and hypertension are increased in patients with systemic lupus erythematosus.

Prematurity is two to four times more common in patients with lupus, with a higher risk in the case of lupus nephritis. In addition, an overlap syndrome between preeclampsia and lupus nephritis may occur in the pregnancy.

Medication allowed during pregnancy is represented by hydroxychloroquine, corticosteroids, non-steroidal antiinflammatory drugs, azathioprine, cyclosporine, tactolimus, biological therapy. The administration of mycophenolate mofetil, lefunomide, cyclophosphamide and mohotrexate is contraindicated.

Conflict of interest disclosure

There are no known conflicts of interest in the publication of this article. The manuscript was read and approved by all authors.

Compliance with ethical standards

Any aspect of the work covered in this manuscript has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

References

1. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Mejía JC, Aydintug AO, Chwalinska-Sadowska H, de Ramón E, Fernández-Nebro A, Galeazzi M, Valen M, Mathieu A, Houssiau F, Caro N, Alba P, Ramos-Casals M, Ingelmo M, Hughes GR; European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. *Medicine (Baltimore)*. 2003;82(5): 299-308. doi: 10.1097/01.md.0000091181.93122.55
2. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. *Arthritis Rheum.* 1999;42(9):1785-96. doi: 10.1002/1529-0131(199909)42:9<1785::AID-ANR1>3.0.CO;2-#
3. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum*. 2012 Aug;64(8):2677-86. doi: 10.1002/art.34473
4. Petri M, Magder L. Classification criteria for systemic lupus erythematosus: a review. *Lupus.* 2004;13(11): 829-37. doi: 10.1191/0961203304lu2019oa
5. Greco CM, Rudy TE, Manzi S. Adaptation to chronic pain in systemic lupus erythematosus: applicability of the multidimensional pain inventory. *Pain Med*. 2003; 4(1):39-50. doi: 10.1046/j.1526-4637.2003.03001.x
6. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. *Arthritis Rheum*. 2005 Feb;52(2):514-21. doi: 10.1002/art.20864
7. Yang H, Liu H, Xu D, Zhao L, Wang Q, Leng X, Zheng W, Zhang F, Tang F, Zhang X. Pregnancy-related systemic lupus erythematosus: clinical features, outcome and risk factors of disease flares--a case control study. *PLoS One.* 2014 Aug 13;9(8):e104375. doi: 10.1371/journal.pone.0104375
8. Kwok LW, Tam LS, Zhu T, Leung YY, Li E. Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. *Lupus*. 2011;20(8):829-36. doi: 10.1177/0961203310397967
9. Buyon JP, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, Sammaritano L, Branch DW, Porter TF, Sawitzke A, Merrill JT, Stephenson MD, Cohn E, Garabet L, Salmon JE. Predictors of Pregnancy

Outcomes in Patients With Lupus: A Cohort Study. *Ann Intern Med*. 2015 Aug 4;163(3):153-63. doi: 10.7326/M14-2235

10. Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: ten questions and some answers. *Lupus*. 2008;17(5):416-20. doi: 10.1177/0961203308090027
11. Lateef A, Petri M. Managing lupus patients during pregnancy. *Best Pract Res Clin Rheumatol*. 2013 Jun;27(3):435-47. doi: 10.1016/j.berh.2013.07.005
12. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. *Clin J Am Soc Nephrol*. 2010 Nov;5(11):2060-8. doi: 10.2215/CJN.00240110
13. Petri M. Prospective study of systemic lupus erythematosus pregnancies. *Lupus*. 2004;13(9):688-9. doi: 10.1191/0961203303lu2006oa
14. Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. *Arthritis Rheum*. 2006;54(11):3640-7. doi: 10.1002/art.22159
15. Gladman DD, Tandon A, Ibañez D, Urowitz MB. The effect of lupus nephritis on pregnancy outcome and fetal and maternal complications. *J Rheumatol*. 2010 Apr;37(4):754-8. doi: 10.3899/jrheum.090872
16. Saavedra MA, Cruz-Reyes C, Vera-Lastra O, Romero GT, Cruz-Cruz P, Arias-Flores R, Jara LJ. Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy. *Clin Rheumatol*. 2012 May;31(5):813-9. doi: 10.1007/s10067-012-1941-4
17. Saavedra MA, Sánchez A, Morales S, Navarro-Zarza JE, Ángeles U, Jara LJ. Primigravida is associated with flare in women with systemic lupus erythematosus. *Lupus*. 2015;24(2):180-5. doi: 10.1177/0961203314552116
18. Borella E, Lojacono A, Gatto M, Andreoli L, Taglietti M, Iaccarino L, Casiglia E, Punzi L, Tincani A, Doria A. Predictors of maternal and fetal complications in SLE patients: a prospective study. *Immunol Res*. 2014 Dec;60(2-3):170-6. doi: 10.1007/s12026-014-8572-6
19. Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. *Am J Obstet Gynecol*. 2008 Aug;199(2): 127.e1-6. doi: 10.1016/j.ajog.2008.03.012
20. Yasmeen S, Wilkins EE, Field NT, Sheikh RA, Gilbert WM. Pregnancy outcomes in women with systemic lupus erythematosus. *J Matern Fetal Med*. 2001 Apr; 10(2):91-6. doi: 10.1080/714904302
21. Chakravarty EF, Colón I, Langen ES, Nix DA, El-Sayed YY, Genovese MC, Druzin ML. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. *Am J Obstet Gynecol*. 2005 Jun;192(6):1897-904. doi: 10.1016/j.ajog.2005.02.063
22. Bramham K, Hunt BJ, Bewley S, Germain S, Calatayud I, Khamashta MA, Nelson-Piercy C. Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. *J Rheumatol*. 2011 Sep; 38(9):1906-13. doi: 10.3899/jrheum.100997
23. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. *Eur J Obstet Gynecol Reprod Biol*. 2013;170(1):1-7. doi: 10.1016/j.ejogrb.2013.05.005
24. Gibbins KJ, Ware Branch D. Pre-eclampsia as a manifestation of antiphospholipid syndrome: assessing the current status. *Lupus*. 2014 Oct;23(12):1229-31. doi: 10.1177/0961203314531347
25. Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP, Muscarà M, Vignati G, Stramba-Badiale M, Catelli L, Lojacono A, Cavazzana I, Ghirardello A, Vescovi F, Gambari PF, Doria A, Meroni PL, Tincani A. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. *Arthritis Rheum*. 2001 Aug;44(8):1832-5. doi: 10.1002/1529-0131(200108)44:8<1832::AID-ART320>3.0.CO;2-C
26. Askanase AD, Miranda-Carus ME, Tang X, Katholi M, Buyon JP. The presence of IgG antibodies reactive with components of the SSA/Ro-SSB/La complex in human breast milk: implications in neonatal lupus. *Arthritis Rheum*. 2002 Jan;46(1):269-71. doi: 10.1002/1529-0131(200201)46:1<269::AID-ART10043>3.0.CO;2-6
27. Lockshin MD, Sammaritano LR. Lupus pregnancy. *Autoimmunity*. 2003 Feb;36(1):33-40. doi: 10.1080/0891693031000067313
28. Buyon JP, Cronstein BN, Morris M, Tanner M, Weissmann G. Serum complement values (C3 and C4) to differentiate between systemic lupus activity and pre-eclampsia. *Am J Med*. 1986 Aug;81(2):194-200. doi: 10.1016/0002-9343(86)90251-2
29. Buyon JP, Tamerius J, Ordorica S, Young B, Abramson SB. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. *Arthritis Rheum*. 1992 Jan;35(1):55-61. doi: 10.1002/art.1780350109
30. Clowse ME, Magder LS, Petri M. The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. *J Rheumatol*. 2011 Jun;38(6):1012-6. doi: 10.3899/jrheum.100746
31. Wieser MN, Gourounti K, Sarantaki A. Modes of birth and their impact on the psychological and physical health of women. *J Mind Med Sci*. 2021;8(1):1-4. doi: 10.22543/7674.81.P14
32. Al-Herz A, Schulzer M, Esdaile JM. Survey of antimalarial use in lupus pregnancy and lactation. *J Rheumatol*. 2002 Apr;29(4):700-6.

33. Levy RA, Vilela VS, Cataldo MJ, Ramos RC, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. *Lupus*. 2001;10(6):401-4. doi: 10.1191/096120301678646137
34. Balalau OD, Loghin MG, Vasilache S, Olaru OG, Paunica I, Conea IM. Uterine submucosal leiomyomas: modern diagnosis and miniinvasive surgery. *J Clin Investig Surg*. 2021;6(2):88-93. doi: 10.25083/2559.5555/6.2.2
35. Uzun ND, Tekin M, Uzun F. A comprehensive analysis of postpartum depression and delivery characteristics: a cross-sectional study. *J Mind Med Sci*. 2021;8(1):94-99. doi: 10.22543/7674.81.P9499
36. Suceveanu AI, Pantea Stoian A, Parepa I, Voinea C, Hainarosie R, Manuc D, Nitipir C, Mazilu L, Suceveanu AP. Gut Microbiota Patterns in Obese and Type 2 Diabetes (T2D) Patients from Romanian Black Sea Coast Region. *Revista de Chimie (Rev. Chim.)*. 2018;69(8):2260-2267. doi: 10.37358/RC.18.8.6512
37. Stanescu AD, Loghin MG, Ples L, et al. Therapeutic approach of uterine leiomyoma; choosing the most appropriate surgical option. *J Clin Investig Surg*. 2021; 6(1):1-5. doi: 10.25083/2559.5555/6.1.1
38. Izmirly P, Saxena A, Buyon JP. Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus. *Curr Opin Rheumatol*. 2017 Sep;29(5): 467-472. doi: 10.1097/BOR.0000000000000414
39. Muñoz CM, Goulden B, Ahmed K, Alijotas-Reig J, Giles I. Risk of adverse pregnancy outcomes prior to the onset of an autoimmune rheumatic disease: a systematic review. *Rheumatology (Oxford)*. 2022 Aug 5:keac417. doi: 10.1093/rheumatology/keac417
40. Ardeleanu V, Andronache LF, Gherghiceanu F, Paunica S, Balalau C, Pantea Stoian A. Treatment of lipomas and diffuse lipomatosis with NDYAG 1064 NM laser and their impact on the quality of life. *J Mind Med Sci*. 2020; 7(1):16-22. doi: 10.22543/7674.71.P1622
41. US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Kubik M, Li L, Ogedegbe G, Pbert L, Silverstein M, Simon MA, Stevermer J, Tseng CW, Wong JB. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2021 Sep 28;326(12):1186-1191. doi: 10.1001/jama.2021.14781
42. Valviesse DMJ, Monteiro DLM, Jésus NR, Jésus GRR, Santos FC, Lacerda MI, Rodrigues NCP, Klumb EM. Risk factors associated with infections in pregnant women with systemic lupus erythematosus. *Rev Assoc Med Bras (1992)*. 2022 Apr;68(4):536-541. doi: 10.1590/1806-9282.20220074
43. Savu C, Melinte A, Posea R, Galie N, Balescu I, Diaconu C, Cretoiu D, Dima S, Filipescu A, Balalau C, Bacalbasa N. Pleural Solitary Fibrous Tumors-A Retrospective Study on 45 Patients. *Medicina (Kaunas)*. 2020 Apr 16;56(4):185. doi: 10.3390/medicina56040185
44. Bălălău OD, Olaru OG, Dumitru AV, et al. Maternal infections with an increased risk of transmission to the foetus; a literature review. *J Clin Investig Surg*. 2020; 5(2):66-72. doi: 10.25083/2559.5555/5.2/66.72
45. Webster P, Wardle A, Bramham K, Webster L, Nelson-Piercy C, Lightstone L. Tacrolimus is an effective treatment for lupus nephritis in pregnancy. *Lupus*. 2014 Oct;23(11):1192-6. doi: 10.1177/0961203314540353
46. Ichinose K, Sato S, Kitajima Y, Horai Y, Fujikawa K, et al. The efficacy of adjunct tacrolimus treatment in pregnancy outcomes in patients with systemic lupus erythematosus. *Lupus*. 2018 Jul;27(8):1312-1320. doi: 10.1177/0961203318770536
47. Aliuș C, Bacalbașa N, Bălălău C. Innovative Device for Indocianyne Green Navigational Surgery. *J Mind Med Sci*. 2020;7(1):40-45. doi: 10.22543/7674.71.P4045
48. Suzuki K, Uno S, Wakasugi N. Tacrolimus Use and Renal Function in Pregnancy with Lupus Nephritis: Analysis of Post-Marketing Surveillance Data in Japan. *Mod Rheumatol*. 2022 Aug 19:roac094. doi: 10.1093/mr/roac094
49. Stanescu AD, Balalau DO, Ples L, Paunica S, Balalau C. Postpartum depression: Prevention and multimodal therapy. *J Mind Med Sci*. 2018;5(2):163-168. doi: 10.22543/7674.52.P163168
50. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis*. 2019 Sep;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819
51. Temprano KK, Bandlamudi R, Moore TL. Antirheumatic drugs in pregnancy and lactation. *Semin Arthritis Rheum*. 2005 Oct;35(2):112-21. doi: 10.1016/j.semarthrit.2005.05.002
52. Fayad F, Ziade N, Karam GA, Ghaname W, Khamashta M. Rheumatic diseases and pregnancy: a national survey about practice patterns among rheumatologists and obstetricians. *Clin Exp Rheumatol*. 2018 Nov-Dec;36(6):1014-1021.